The pharmaceutical industry is no stranger to navigating complex access landscapes, and the forthcoming implementation of the Joint Clinical Assessment (JCA) under the EU’s new Health Technology Assessment (HTA) regulation marks a significant shift. Scheduled to take effect this year, JCA introduces a unified framework for assessing the clinical value of medicines, starting with oncology and advanced therapy medicinal products (ATMPs). While this initiative promises to streamline market access across EU member states, it also presents new challenges for pharmaceutical companies. Fortunately, advancements in artificial intelligence (AI) offer practical solutions to address these hurdles.
The Impacts of JCA on Pharma Companies
The JCA aims to harmonise clinical evaluations across the EU, reducing duplication of effort for pharmaceutical companies and national HTA bodies. However, it brings with it a range of challenges:
Increased Complexity in Evidence Requirements: The JCA will rely on the PICO (Population, Intervention, Comparator, Outcome) framework to define research questions, considering expectations of all the member EU states. Companies will need to tackle submission packages for all EU markets together, making evidence submission more intricate considering the permutations of PICOs possible representing the differences in management across the different EU countries.
Heightened Pressure on Timelines: The centralised process demands earlier and comprehensive submission of data. Pharma companies must adapt their evidence planning and generation processes to align with JCA timelines, leaving little room for delays.
Potential for Divergent National Decisions: While the JCA harmonises clinical assessments, reimbursement decisions remain the prerogative of individual member states. Companies may face the dual burden of adhering to centralised requirements while addressing national-level variations.
Resource-Intensive Data Management: Preparing for JCA involves gathering, consolidating, and analysing vast amounts of data from clinical trials, real-world evidence, and historical HTA decisions—a time-consuming and resource-intensive process.
How AI Can Help Pharma Companies Adapt
Artificial intelligence (AI), with its ability to process and analyse complex datasets, offers transformative solutions to help pharmaceutical companies navigate the challenges of JCA.
Here’s how AI can come to the rescue:
Predicting JCA Requirements: AI algorithms can analyse historical HTA data and identify patterns in PICO requests. By predicting the likely PICO scenarios for specific therapeutic areas, companies can proactively adjust their evidence generation strategies, reducing the risk of data gaps and ensuring alignment with JCA expectations.
Streamlining Evidence Generation: AI-powered tools can automate the extraction and synthesis of data from diverse sources, such as clinical trial results, scientific literature, and HTA reports. This not only accelerates the preparation of submissions but also ensures consistency and accuracy in the data presented.
Optimising Cross-Market Analysis: AI platforms can provide comparative analyses of competitor outcomes across major markets, helping companies understand relative clinical benefits and anticipate JCA’s evaluation criteria. These insights enable more strategic planning of evidence generation and submission.
Facilitating Collaboration and Communication: AI-driven dashboards and visualisation tools can consolidate data from multiple regions and stakeholders, providing a unified view of launch readiness and HTA submissions. This fosters better coordination across teams and enhances decision-making.
Reducing Resource Strain: By automating labour-intensive processes such as data extraction, cleaning, and analysis, AI reduces the burden on teams. This allows resources to be reallocated to higher-value activities, such as strategic planning and stakeholder engagement.
Conclusion
The introduction of the JCA represents a pivotal moment for pharmaceutical companies operating in the EU. While it offers the potential for greater efficiency in market access, it also demands a new level of rigour and coordination in evidence generation and submission. Artificial Intelligence, with its ability to streamline complex processes and generate actionable insights, is poised to be a critical enabler in this transition. By leveraging AI solutions, pharma companies can not only meet the challenges of JCA head-on but also gain a competitive edge in the evolving regulatory landscape.
As the industry prepares for 2025, those who invest in AI-driven tools and strategies today will be best positioned to succeed in the new era of HTA. The question is no longer whether to embrace AI but how quickly and effectively it can be integrated into existing workflows.
If you are interested in learning how our Evidence Hub JCA Navigator can support your organisation in navigating these changes, find out more to schedule a discussion.
